TMC preps filings for inclisiran after final phase 3 trials hit the mark

Less frequent dosing schedules could prove an advantage over rivals. The Medicines Company has positive top-line data from the last of its phase 3 trials of inclisiran, setting up regulatory ... The ORION-9 and ORION-10 data will be reported in full at

TMC’s full data for inclisiran impresses at ESC

Marketing applications expected before end of year. The Medicine’s Company has unveiled the impressive detailed results of its LDL-C lowering drug inclisiran at the ESC 2019, setting up a ... By lowering LDL levels, or ‘bad’ cholesterol, the

TMC rockets on data for twice-yearly cholesterol drug inclisiran

Shares up 14% following announcement. The Medicines Company’s big gamble on cholesterol-lowering drug inclisiran looks like to could be about to pay off with a US filing later this ... Shares in the company closed up 14% after the ORION-11 data was

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

company. The company points out that its European summary of product characteristics (SmPC) lists data from APOLLO on primary and secondary endpoints, including exploratory cardiac endpoints - long term data from it ... Alnylam has three more RNAi

1 2 3 4 5 6 [ Next 5 results ]